Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Innate Pharma (IPHA)
NASDAQ:IPHA
Holding IPHA?
Track your performance easily
IPHA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.29 - $3.51
Previous Close$2.11
Volume101.58K
Average Volume (3M)483.78K
Market Cap
$168.30M
Enterprise Value$121.47M
Total Cash (Recent Filing)$92.46M
Total Debt (Recent Filing)$47.54M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Mar 27, 2025EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding80,453,282
10 Day Avg. Volume1,514,293
30 Day Avg. Volume483,776
Standard Deviation0.18
R-Squared0.00684
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)3.25
Price to Sales (P/S)2433109.43
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.97
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.25Price Target Upside323.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Innate Pharma News
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentPositive FDA feedback on lacutamab with potential accelerated approval in Sézary syndrome.
Financial StabilityInnate Pharma has sufficient cash reserves to fund operations through 2025.
Pipeline DiversityInnate Pharma has one of the most diverse pipelines of a company its size, with seven clinical assets and four therapeutic approaches.
Bears Say
Clinical TrialsUncertainty in the timing of the confirmation trial is an overhang for stock appreciation of lacutamab’s value.
Treatment Side EffectsEV treatment was associated with high rates of peripheral neuropathy, skin toxicity, and ocular toxicity, leading to frequent dose interruption and discontinuation.
Trial ExecutionThe biggest risk to the company going into 2025 is slow trial execution, particularly with IPH6501 and IPH4502.
---
Ownership Overview
―
Insiders
0.10% Other Institutional Investors
99.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IPHA FAQ
What was Innate Pharma’s price range in the past 12 months?
Innate Pharma lowest stock price was $1.29 and its highest was $3.51 in the past 12 months.
What is Innate Pharma’s market cap?
Currently, no data Available
When is Innate Pharma’s upcoming earnings report date?
Innate Pharma’s upcoming earnings report date is Mar 27, 2025 which is in 86 days.
How were Innate Pharma’s earnings last quarter?
Innate Pharma released its earnings results on Sep 12, 2024. The company reported -$0.342 earnings per share for the quarter, missing the consensus estimate of -$0.3 by -$0.042.
Is Innate Pharma overvalued?
According to Wall Street analysts Innate Pharma’s price is currently Undervalued.
Does Innate Pharma pay dividends?
Innate Pharma does not currently pay dividends.
What is Innate Pharma’s EPS estimate?
Innate Pharma’s EPS estimate is -$0.27.
How many shares outstanding does Innate Pharma have?
Innate Pharma has 82,802,250 shares outstanding.
What happened to Innate Pharma’s price movement after its last earnings report?
Innate Pharma reported an EPS of -$0.342 in its last earnings report, missing expectations of -$0.3. Following the earnings report the stock price went down -3.39%.
Which hedge fund is a major shareholder of Innate Pharma?
Currently, no hedge funds are holding shares in IPHA
---
Innate Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.25 (323.08% Upside)
$8.25 (323.08% Upside)
Blogger Sentiment
Bullish
IPHA Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.71%
12-Months-Change
Fundamentals
Return on Equity
-78.33%
Trailing 12-Months
Asset Growth
-25.23%
Trailing 12-Months
Company Description
Innate Pharma
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies.
---
IPHA Company Deck
---
IPHA Earnings Call
Q2 2024
0:00 / 0:00
---
IPHA Stock 12 Month Forecast
Average Price Target
$8.25
▲(323.08% Upside)
Technical Analysis
Best Analysts Covering IPHA
1 Year
1 Year Success Rate
5/17 ratings generated profit
1 Year Average Return
-8.98%
reiterated a buy rating 22 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 29.41% of your transactions generating a profit, with an average return of -8.98% per trade.
---